TwitterRSSFacebookDirectors Blog
  Disorders A - Z:   A    B   C    D    E    F    G    H    I    J    K    L    M    N    O    P    Q    R    S    T    U    V    W    X    Y    Z

Skip secondary menu

Funding News - Research on the Role of Antioxidants in the Prevention of Diabetic Complications Encouraged

Archive folder iconHistorical Data

  • The information on this page is for historical and research purposes only.
  • For the most current NINDS funding announcements, please see the NINDS list of Active Funding Initiatives or Follow Us on Twitter for the latest funding news.

The National Institute of Neurological Disorders and Stroke (NINDS), the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), the National Eye Institute (NEI), the National Heart, Lung, and Blood Institute (NHLBI), the National Institute on Aging (NIA), and the Office of Dietary Supplements encourage grant applications for research on the use of antioxidants to prevent diabetic complications.* Prevention and treatment of long-term complications remain a critical problem in the management of type 1 and type 2 diabetes. In the United States, diabetes is the leading cause of new blindness in working-age adults, of new cases of end-stage renal disease, and of non-traumatic lower leg amputations. In addition, cardiovascular complications are now the leading cause of diabetes-related morbidity and mortality, particularly among women and the elderly. Examples of potential research include studies to: determine the mechanism(s) by which antioxidant(s) prevent or influence the development of diabetic vascular disease, including neurovascular and cerebrovascular disease; define interactions between oxidative pathways and free radical formation and the signaling pathways by which insulin, glucose, and other factors affect the endothelium; investigate genetic factors that may affect susceptibility by which oxidative stress and antioxidant therapies affect microvascular and macrovascular disease in diabetes; assess metabolism and tissue distribution, determine kinetics, and establish optimal dosing regimens for vitamin E or other antioxidants in patients with diabetes and/or diabetic complications; establish valid surrogate markers or clinical endpoints of diabetic complications that could be used in phase III trials of antioxidants; determine clinically meaningful, state-of-the-art measures of oxidant/antioxidant status of patients with diabetes; compare antioxidants to establish which are most likely to be efficacious in diabetic complications, or to define specific subpopulations who are most likely to benefit from antioxidant intervention; and develop new strategies to inhibit oxidation/glycoxidation and examine the effect of these strategies on microvascular or cardiovascular disease. For more information, potential applicants should contact Dr. Paul Nichols, Program Director, Systems and Cognitive Neuroscience Cluster, NINDS, Neuroscience Center, 6001 Executive Boulevard, Room 2118, Bethesda, MD, 20892; telephone: (301) 496-9964; fax: (301) 401-2060; e-mail:

*For a more detailed description of this program announcement, please visit the NIH web site at: